Jessica Laury, Kaitlin Forsberg, Elizabeth L. Berkow, Sophie Jones, D. Joseph Sexton, Dawn Sievert, Shawn R. Lockhart, Jeremy A.W. Gold, Meghan Lyman
During 2022-2023, the Antimicrobial Resistance Laboratory Network tested 8,033 Candida auris clinical isolates in the United States. Overall, 95% of isolates were fluconazole resistant, 15% amphotericin B resistant, and 1% echinocandin resistant. Laboratory capacity for C. auris identification and antifungal susceptibility testing is essential to address this emerging public health threat.